MedTrace Logo

Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)

NCT04416100 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2020-12-02

No results posted yet for this study

Summary

COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected.The most common computed tomographic changes in acute lung injury include bilateral and subpleural milk glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur. The most prominent radiological changes occur around day 10, followed by gradual resolution, which begins two weeks after the onset of symptoms.

Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both.

Here, the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, HR-CT scans, and by determining the "immunofibrotic" pattern in peripheral mononuclear cells (PBMCs) 1, 3, and 6 months after discharge.

Conditions

Interventions

DIAGNOSTIC_TEST

Pulmonary function tests

Spirometry or plethysmography, measurement of diffusion capacity

DIAGNOSTIC_TEST

Imaging

HRCT and echocardiography as scheduled within routine clinical examinations

BIOLOGICAL

Blood sampling

Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping

Sponsors & Collaborators

Principal Investigators

  • Ivan Tancevski, Doz. Dr. · Medical University Innsbruck, Department Internal Medicine II

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-29
Primary Completion
2022-04-28
Completion
2022-04-28

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04416100 on ClinicalTrials.gov